Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Total 13F shares
-
108,291,108
-
Share change
-
+12,527,818
-
Total reported value
-
$394,183,978
-
Put/Call ratio
-
196%
-
Price per share
-
$3.64
-
Number of holders
-
157
-
Value change
-
+$56,486,637
-
Number of buys
-
109
-
Number of sells
-
41
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2025
As of 30 Jun 2025 Akebia Therapeutics, Inc. - Common Stock (AKBA) had 157 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 108,291,108 shares of stock of the company.
Largest 10 holders included BlackRock, Inc., VANGUARD GROUP INC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, GOLDMAN SACHS GROUP INC, MPM BIOIMPACT LLC, Nuveen, LLC, and FRANKLIN RESOURCES INC.
This table shows 157 institutional shareholders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.